Premium
Adjuvant chemoimmunotherapy stage i/ii malignant melanoma
Author(s) -
Knost J. A.,
Reynolds V.,
Greco F. A.,
Oldham R. K.
Publication year - 1982
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.2930190311
Subject(s) - chemoimmunotherapy , medicine , melanoma , stage (stratigraphy) , concomitant , adjuvant , dissection (medical) , surgery , dacarbazine , oncology , chemotherapy , cyclophosphamide , cancer research , paleontology , biology
Sixty patients with Stage I or Stage II malignant melanoma were treated with wide local excision of the primary and dissection of the regional lymph nodes prior to being randomized to chemoimmunotherapy with DTIC plus intradermal BCG versus methyl‐CCNU plus intradermal BCG. For the 32 Stage I patients, there were no differences in survival between the two treatment groups. Survival was similar to a concomitant control group of 45 Stage I patients. For Stage II melanoma both chemoimmunotherapy groups had a significantly better survival than the 11 patients in the untreated control group. These results do not indicate that this form of chemoimmunotherapy is valuable in Stage I malignant melanoma but further trials are needed for patients with Stage II disease.